MET-X, a novel metallo-beta-lactamase (MBL) inhibitor, has shown best-in-class performance in preclinical studies
EMBLAVEOTM is the first and only monobactam/?-lactamase inhibitor combination antibiotic therapy approved by the USFDA
The overall clinical efficacy of Zaynich across indications was 98% at the test-of-cure
AMR poses a critical threat to global public health undermining decades of progress made in the field of modern medicine
The launch of Cefepime-Enmetazobactam marks a significant milestone for India's pharmaceutical industry in fight against AMR
The Gavi Board today approved the Vaccine Alliance's strategy for the five-year period running from 2026 to 2030
DCGI has also granted permission to manufacture and market FDF of Cefepime and Enmetazobactam as a dry powder injectable
Empowering Research, Enhancing Proficiency is the theme of this year’s Homoeopathic Symposium
With just few days of treatment, the patient started responding well and finally complete clinical resolution of infection was attained
Orchid is the first company from India, ever to have invented a product which has received a New Drug Approval (NDA) from USFDA
Subscribe To Our Newsletter & Stay Updated
